{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T19:17:23Z","timestamp":1788463043797,"version":"build-2803163510"},"reference-count":22,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Antiblastic Drugs Units (ADUs) ensure safety, appropriateness and sustainability of oncology treatments. Over the last decade, hospital pharmacists have expanded their role from aseptic compounding to advanced clinical pharmacy. This study describes the ten-year evolution of the ADU of ASL Taranto in Southern Italy, focusing on clinical, organisational and strategic value generated from 2014 to 2025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective descriptive analysis of activity data, organisational changes and clinical pharmacy services was conducted. Key indicators include compounded preparations, quality systems, technological innovations, service centralisation, CAR-T therapy management, clinical trials, compassionate use programmes and COVID-19 emergency response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Between March and December 2014, 17,508 antiblastic preparations were compounded (daily average: 83). Activity increased to 53,300 in 2025 (daily average: 212), representing a 204% increase. The ADU achieved and maintained ISO 9001:2015 certification since 2017. Since 2022, 49 CAR-T therapies were managed, including quality assurance and AIFA registry monitoring. The ADU evolved into a Clinical Trial Centre, supporting six phase II-III trials in 2025, and enabled access to innovative medicines through compassionate use programmes (62 patients in 2025). During COVID-19, the unit served as central hub for vaccine and remdesivir management. Despite a 1194% increase in pharmaceutical expenditure (\u20ac2.54\u2005M to \u20ac32.87\u2005M), systematic reimbursement management generated \u20ac8.92\u2005M in recoveries and savings in 2025 (27.1% of expenditure).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The experience of this ADU illustrates how a structured, quality-driven approach can support the transformation of aseptic compounding into advanced clinical pharmacy. The integration of pharmacists into multidisciplinary oncology teams was associated with strengthened medication safety processes, expanded access to innovation and improved economic sustainability, suggesting a potential reference model for comparable settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552261481419","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T15:07:25Z","timestamp":1788275245000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["From supportive galenic compounding to advanced clinical pharmacy: A decade of excellence and safety in the Antiblastic Drugs Unit in Southern Italy (2014\u20132025)"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-7330-8215","authenticated-orcid":false,"given":"Filomena","family":"D'Amico","sequence":"first","affiliation":[{"name":"ASL Taranto"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Moscogiuri","sequence":"additional","affiliation":[{"name":"ASL Taranto"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loredana","family":"Brandi","sequence":"additional","affiliation":[{"name":"ASL Taranto"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Colasuonno","sequence":"additional","affiliation":[{"name":"ASL Taranto"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariangela","family":"Calcagno","sequence":"additional","affiliation":[{"name":"University of Foggia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Maggi","sequence":"additional","affiliation":[{"name":"Hospital \u201cSan G. Moscati\u201d, ASL Taranto"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Ingrosso","sequence":"additional","affiliation":[{"name":"Hospital \u201cSan G. Moscati\u201d, ASL Taranto"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziana","family":"Guarino","sequence":"additional","affiliation":[{"name":"Hospital \u201cSan G. Moscati\u201d, ASL Taranto"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Ungaro","sequence":"additional","affiliation":[{"name":"Hospital \u201cSan G. Moscati\u201d, ASL Taranto"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito Gregorio","family":"Colacicco","sequence":"additional","affiliation":[{"name":"General Management, ASL Taranto"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Pisconti","sequence":"additional","affiliation":[{"name":"Hospital \u201cSan G. Moscati\u201d, ASL Taranto"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"e_1_3_2_2_2","first-page":"101","article-title":"Safe preparation of cytotoxic drugs: an overview","volume":"11","author":"Pouplin S","year":"2017","unstructured":"Pouplin S, Gicquel M, Verhaeghe P, et al. Safe preparation of cytotoxic drugs: an overview. Eur J Oncol Pharm 2017; 11: 101\u2013106.","journal-title":"Eur J Oncol Pharm"},{"key":"e_1_3_2_3_2","unstructured":"Connor TH MacKenzie BA DeBord DG et al. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. DHHS (NIOSH) Publication Number 2016-161."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1310\/hpj4803-204"},{"key":"e_1_3_2_5_2","article-title":"2016 Updated American Society of Clinical Oncology\/Oncology Nursing Society chemotherapy administration safety standards including standards for the safe administration and management of oral chemotherapy","volume":"13","author":"Neuss MN","year":"2017","unstructured":"Neuss MN, Gilmore TR, Belderson KM, et al. 2016 Updated American Society of Clinical Oncology\/Oncology Nursing Society chemotherapy administration safety standards including standards for the safe administration and management of oral chemotherapy. J Oncol Pract 2017; 13: e92\u2013e113.","journal-title":"J Oncol Pract"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.2535"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0160221"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoto.2014.1570"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.31"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.11-5-463"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/57.suppl_4.S4"},{"key":"e_1_3_2_12_2","volume-title":"Guideline on registry-based studies. EMA\/502388\/2020","author":"European Medicines Agency","year":"2021","unstructured":"European Medicines Agency. Guideline on registry-based studies. EMA\/502388\/2020. EMA, 2021."},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2013.04.011"},{"key":"e_1_3_2_14_2","volume-title":"Raccomandazione n.14: Raccomandazione per la prevenzione degli errori in terapia con farmaci antineoplastici","author":"Ministero della Salute","year":"2012","unstructured":"Ministero della Salute. Raccomandazione n.14: Raccomandazione per la prevenzione degli errori in terapia con farmaci antineoplastici. Ministry of Health, 2012."},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116133"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00662-6"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155210361431"},{"key":"e_1_3_2_18_2","first-page":"1","article-title":"Quality standard for the oncology pharmacy service (QuapoS 5)","volume":"20","author":"ESOP European Society of Oncology Pharmacy","year":"2014","unstructured":"ESOP European Society of Oncology Pharmacy. Quality standard for the oncology pharmacy service (QuapoS 5). J Oncol Pharm Pract 2014; 20: 1\u201363.","journal-title":"J Oncol Pharm Pract"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12388"},{"key":"e_1_3_2_20_2","article-title":"Management of CAR T-cell therapy-associated toxicity in clinical practice","volume":"11","author":"Penack O","year":"2024","unstructured":"Penack O, Koenecke C, Mohty M, et al. Management of CAR T-cell therapy-associated toxicity in clinical practice. Lancet Haematol 2024; 11: e73\u2013e85.","journal-title":"Lancet Haematol"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz167"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1080\/20016689.2020.1715536"},{"key":"e_1_3_2_23_2","first-page":"111","article-title":"Pharmacists\u2019 role in the COVID-19 pandemic: an Italian perspective","volume":"9","author":"Cadeddu C","year":"2021","unstructured":"Cadeddu C, Mosca D, Castellani S, et al. Pharmacists\u2019 role in the COVID-19 pandemic: an Italian perspective. Pharmacy (Basel) 2021; 9: 111.","journal-title":"Pharmacy (Basel)"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552261481419","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552261481419","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552261481419","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T18:47:07Z","timestamp":1788461227000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552261481419"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":22,"alternative-id":["10.1177\/10781552261481419"],"URL":"https:\/\/doi.org\/10.1177\/10781552261481419","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]},"article-number":"10781552261481419"}}